India’s Jubilant Life Sciences Ltd said on Tuesday it had signed a non-exclusive licensing agreement for selling Gilead Sciences Inc’s experimental COVID-19 treatment Remdesivir in 127 countries, including India.
Gilead earlier this month received the US Food and Drug Administration’s emergency use authorisation for using Remdesivir as a treatment against COVID-19, the respiratory illness caused by the novel coronavirus, after the drug-maker provided data showing the drug had helped patients.
|Bhopal - The City of Lakes|
|HOTELS & RESTAURANTS|
|ART & CULTURE|
|MAJOR TOURIST ATTRACTIONS|
|TECHNICAL UNIVERSITIES & INSTITUTIONS|
|MEDICAL COLLEGES & HOSPITALS|
|UNIVERSITIES & ACADEMIES|
|Tourist Attractions in M.P.|
|NATIONAL PARKS AND WILDLIFE SANCTUARIES|
|HISTORICAL & ARCHAEOLOGICAL IMPORTANT PLACES|
|HERITAGES & MONUMENTS|